IL147489A0 - Use of docetaxel for treating hepatocellular carcinoma - Google Patents

Use of docetaxel for treating hepatocellular carcinoma

Info

Publication number
IL147489A0
IL147489A0 IL14748900A IL14748900A IL147489A0 IL 147489 A0 IL147489 A0 IL 147489A0 IL 14748900 A IL14748900 A IL 14748900A IL 14748900 A IL14748900 A IL 14748900A IL 147489 A0 IL147489 A0 IL 147489A0
Authority
IL
Israel
Prior art keywords
docetaxel
hepatocellular carcinoma
treating hepatocellular
treating
mum
Prior art date
Application number
IL14748900A
Other languages
English (en)
Original Assignee
Aventis Pharma Sa
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Aventis Pharma Sa filed Critical Aventis Pharma Sa
Publication of IL147489A0 publication Critical patent/IL147489A0/xx

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/337—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having four-membered rings, e.g. taxol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents

Landscapes

  • Health & Medical Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Epidemiology (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Epoxy Compounds (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Steroid Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
IL14748900A 1999-08-31 2000-08-29 Use of docetaxel for treating hepatocellular carcinoma IL147489A0 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
GBGB9920548.6A GB9920548D0 (en) 1999-08-31 1999-08-31 Treatment of hepatocellular carcinoma
PCT/EP2000/008782 WO2001015675A2 (en) 1999-08-31 2000-08-29 Use of docetaxel for treating hepatocellular carcinoma

Publications (1)

Publication Number Publication Date
IL147489A0 true IL147489A0 (en) 2002-08-14

Family

ID=10860081

Family Applications (2)

Application Number Title Priority Date Filing Date
IL14748900A IL147489A0 (en) 1999-08-31 2000-08-29 Use of docetaxel for treating hepatocellular carcinoma
IL147489A IL147489A (en) 1999-08-31 2002-01-06 Use of dotaxel in the preparation of a drug for the treatment of hepatocellular carcinoma

Family Applications After (1)

Application Number Title Priority Date Filing Date
IL147489A IL147489A (en) 1999-08-31 2002-01-06 Use of dotaxel in the preparation of a drug for the treatment of hepatocellular carcinoma

Country Status (34)

Country Link
US (2) US20030158249A1 (xx)
EP (1) EP1214061B1 (xx)
JP (1) JP4866522B2 (xx)
KR (1) KR100670416B1 (xx)
CN (1) CN1174748C (xx)
AT (1) ATE269700T1 (xx)
AU (1) AU777583B2 (xx)
BG (1) BG65913B1 (xx)
BR (1) BR0013625A (xx)
CA (1) CA2382294C (xx)
CZ (1) CZ301378B6 (xx)
DE (1) DE60011794T2 (xx)
DK (1) DK1214061T3 (xx)
EA (1) EA004804B1 (xx)
EE (1) EE05124B1 (xx)
ES (1) ES2218223T3 (xx)
GB (1) GB9920548D0 (xx)
HK (1) HK1048944B (xx)
HR (1) HRP20020171A2 (xx)
HU (1) HU228861B1 (xx)
IL (2) IL147489A0 (xx)
ME (1) MEP7809A (xx)
MX (1) MXPA02002041A (xx)
NO (1) NO328527B1 (xx)
NZ (1) NZ517604A (xx)
PL (1) PL212612B1 (xx)
PT (1) PT1214061E (xx)
RS (1) RS50148B (xx)
SI (1) SI1214061T1 (xx)
SK (1) SK286378B6 (xx)
TW (1) TW589180B (xx)
UA (1) UA72927C2 (xx)
WO (1) WO2001015675A2 (xx)
ZA (1) ZA200201408B (xx)

Families Citing this family (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN1268619C (zh) 2003-05-08 2006-08-09 上海迪赛诺化学制药有限公司 多烯紫杉醇三水化合物的制备方法
EP1694660B1 (en) * 2003-12-12 2009-04-08 Quiral Quimica Do Brasil Process for the preparation of anhydrous and hydrated active pharmaceutical ingredients (apis); stable pharmaceutical compositions prepared from the same and uses of said compositions
US7449196B2 (en) * 2004-07-09 2008-11-11 Robert Sabin Anti tumor compositions and methods of use
RU2451510C2 (ru) * 2005-08-31 2012-05-27 АБРАКСИС БАЙОСАЙЕНС, ЭлЭлСи Композиции и способы получения слаборастворимых в воде лекарственных средств с увеличенной стабильностью
BRPI0615292A8 (pt) 2005-08-31 2018-03-06 Abraxis Bioscience Llc composições e métodos para preparação de fármacos de má solubilidade em água com estabilidade aumentada
US9839667B2 (en) 2005-10-14 2017-12-12 Allergan, Inc. Prevention and treatment of ocular side effects with a cyclosporin
US20080081051A1 (en) * 2006-09-28 2008-04-03 Robert Sabin Method of manufacturing anti-tumor and anti-viral compositions
CA2683712A1 (en) * 2007-04-20 2009-01-15 Sun Pharmaceutical Industries Limited Pharmaceutical compositions
FR2917088B1 (fr) * 2007-06-08 2009-09-04 Aventis Pharma Sa Dissolution directe du docetaxel dans un solvant dans le polysorbate 80
US8541360B2 (en) * 2008-11-19 2013-09-24 Ben Venue Laboratories, Inc. Parenteral formulations comprising sugar-based esters and ethers
CA3051495A1 (en) 2010-03-26 2011-09-29 Abraxis Bioscience, Llc Use of nanoparticles comprising a taxane and albumin in the treatment of hepatocellular carcinoma
KR101752944B1 (ko) * 2010-05-03 2017-07-03 테이코쿠 팔마 유에스에이, 인코포레이티드 비수성의 탁산 프로에멀젼 제제, 및 그의 제조 및 사용 방법
US8842114B1 (en) 2011-04-29 2014-09-23 Nvidia Corporation System, method, and computer program product for adjusting a depth of displayed objects within a region of a display
JO3685B1 (ar) * 2012-10-01 2020-08-27 Teikoku Pharma Usa Inc صيغ التشتيت الجسيمي للتاكسين غير المائي وطرق استخدامها
CA2976912A1 (en) * 2015-02-17 2016-08-25 Mallinckrodt Llc Modified docetaxel liposome formulations and uses thereof

Family Cites Families (20)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR2601675B1 (fr) * 1986-07-17 1988-09-23 Rhone Poulenc Sante Derives du taxol, leur preparation et les compositions pharmaceutiques qui les contiennent
FR2629819B1 (fr) * 1988-04-06 1990-11-16 Rhone Poulenc Sante Procede de preparation de derives de la baccatine iii et de la desacetyl-10 baccatine iii
US5543154A (en) * 1991-12-27 1996-08-06 Merck & Co., Inc. Controlled release nifedipine delivery device
EP0680320B1 (en) * 1993-01-19 1999-04-14 Warner-Lambert Company Stable oral ci-981 formulation and process of preparing same
US5846945A (en) * 1993-02-16 1998-12-08 Onyx Pharmaceuticals, Inc. Cytopathic viruses for therapy and prophylaxis of neoplasia
US5436243A (en) * 1993-11-17 1995-07-25 Research Triangle Institute Duke University Aminoanthraquinone derivatives to combat multidrug resistance
FR2718963B1 (fr) * 1994-04-25 1996-05-24 Rhone Poulenc Rorer Sa Nouvelle composition pharmaceutique à base de taxoïdes.
FR2722191B1 (fr) * 1994-07-08 1996-08-23 Rhone Poulenc Rorer Sa Procede de preparation du trihydrate du (2r,3s)-3-tertbutoxycarbonylamino-2-hydroxy-3-phenylpropionate de 4-acetoxy2alpha-benzoyloxy-5beta,20epoxy-1,7beta,10beta trihydroxy-9-oxo-tax-11-en-13alpha-yle
US6245805B1 (en) * 1995-10-26 2001-06-12 Baker Norton Pharmaceuticals, Inc. Method, compositions and kits for increasing the oral bioavailability of pharmaceutical agents
US5968972A (en) 1995-10-26 1999-10-19 Baker Norton Pharmaceuticals, Inc. Method for increasing the oral bioactivity of pharmaceutical agents
FR2742751B1 (fr) * 1995-12-22 1998-01-30 Rhone Poulenc Rorer Sa Nouveaux taxoides, leur preparation et les compositions pharmaceutiques qui les contiennent
US6503893B2 (en) * 1996-12-30 2003-01-07 Bone Care International, Inc. Method of treating hyperproliferative diseases using active vitamin D analogues
CA2628857C (en) * 1996-12-30 2011-09-13 Batelle Memorial Institute Formulation and method for treating neoplasms by inhalation
EP1023050B1 (en) * 1997-06-27 2013-09-25 Abraxis BioScience, LLC Novel formulations of pharmacological agents, methods for the preparation thereof and methods for the use thereof
JP3775780B2 (ja) * 1997-09-18 2006-05-17 ジヤンセン・フアーマシユーチカ・ナームローゼ・フエンノートシヤツプ 薬剤の経口的バイオアベイラビリテイを向上させるための縮合イミダゾール誘導体
JP4738592B2 (ja) * 1997-10-31 2011-08-03 アーチ・デヴェロップメント・コーポレイション ５α−還元酵素活性を調節するための方法及び組成物
UA73092C2 (uk) * 1998-07-17 2005-06-15 Брістол-Майерс Сквібб Компані Таблетка з ентеросолюбільним покриттям і спосіб її приготування
BR9916536A (pt) * 1998-12-23 2002-01-02 Searle & Co Método para o tratamento ou prevenção de um distúrbio de neoplasia em um mamìfero em necessidade deste tratamento ou prevenção, e, combinação
GB9909925D0 (en) * 1999-04-29 1999-06-30 Pharmacia & Upjohn Spa Combined preparations comprising anthracycline derivatives
US8080672B2 (en) * 2005-12-13 2011-12-20 Teva Pharmaceutical Industries Ltd. Crystal form of atorvastatin hemi-calcium and processes for preparation thereof

Also Published As

Publication number Publication date
EE05124B1 (et) 2009-02-16
DE60011794D1 (de) 2004-07-29
PT1214061E (pt) 2004-09-30
SK286378B6 (sk) 2008-08-05
TW589180B (en) 2004-06-01
HUP0203197A2 (hu) 2003-01-28
HU228861B1 (hu) 2013-06-28
ES2218223T3 (es) 2004-11-16
PL353198A1 (en) 2003-11-03
BG106460A (bg) 2002-09-30
KR20020060166A (ko) 2002-07-16
WO2001015675A2 (en) 2001-03-08
ZA200201408B (en) 2003-07-30
CN1174748C (zh) 2004-11-10
WO2001015675A3 (en) 2001-09-20
DK1214061T3 (da) 2004-11-01
EP1214061B1 (en) 2004-06-23
PL212612B1 (pl) 2012-10-31
HK1048944B (zh) 2005-04-22
CN1372466A (zh) 2002-10-02
EE200200087A (et) 2003-04-15
IL147489A (en) 2006-06-11
ME00624B (me) 2011-12-20
SK2712002A3 (en) 2002-07-02
MEP7809A (en) 2011-12-20
EA200200313A1 (ru) 2002-08-29
CA2382294A1 (en) 2001-03-08
NZ517604A (en) 2004-04-30
ATE269700T1 (de) 2004-07-15
AU7516800A (en) 2001-03-26
AU777583B2 (en) 2004-10-21
KR100670416B1 (ko) 2007-01-17
NO20020829L (no) 2002-02-20
CZ2002739A3 (cs) 2002-06-12
EA004804B1 (ru) 2004-08-26
HK1048944A1 (en) 2003-04-25
MXPA02002041A (es) 2002-08-20
CZ301378B6 (cs) 2010-02-03
NO20020829D0 (no) 2002-02-20
JP4866522B2 (ja) 2012-02-01
BR0013625A (pt) 2002-05-14
HRP20020171A2 (en) 2004-02-29
CA2382294C (en) 2008-06-03
US20080045584A1 (en) 2008-02-21
BG65913B1 (bg) 2010-05-31
SI1214061T1 (en) 2004-12-31
DE60011794T2 (de) 2005-07-14
NO328527B1 (no) 2010-03-08
RS50148B (sr) 2009-05-06
US20030158249A1 (en) 2003-08-21
GB9920548D0 (en) 1999-11-03
YU11402A (sh) 2005-07-19
UA72927C2 (uk) 2005-05-16
JP2003508427A (ja) 2003-03-04
EP1214061A2 (en) 2002-06-19
HUP0203197A3 (en) 2005-01-28

Similar Documents

Publication Publication Date Title
ZA200201408B (en) Use of docetaxel for treating hepatocellular carcinoma.
GB0223038D0 (en) Therapeutic compounds
GB0225474D0 (en) Therapeutic agents
PL365285A1 (en) Pharmaceutical combinations for the treatment of cancer comprising dioxolane nucleoside analogs
MXPA05012323A (es) Sulfonamidas ciclicas para la inhibicion de gama-secretasa.
NZ515567A (en) Method for treating chronic pain using MEK inhibitors
DE60204966D1 (de) Verwendung von cyclopamine zur Herstellung eines Arzneimittels zur Behandlung von Psoriasis
IL192181A0 (en) Use of benzo-fused heterocycle sulfamide derivatives for the treatment of mania and bipolar disorder
WO2004007676A3 (en) Combination therapy for the treatment of neoplasms
IL170519A (en) Use of fenofibrate or pharmaceutically acceptable salt thereof, orlistat and pharmaceutically acceptable carrier in the manufacture of medicaments for the treatment of obesity and pharmaceutical compositions containing them
PL1603584T3 (pl) Aplidyna do leczenia szpiczaka mnogiego
ATE359808T1 (de) Verwendung von sarp-1 zur behandlung und/oder vorbeugung von scleroderma
MXPA05002477A (es) Asialo-interferones y el tratamiento de cancer de higado.
UA34199A (uk) Спосіб лікування пародонтиту
TW200505836A (en) Cyclic sulfonamides for inhibition of gamma-secretase
DE60208336D1 (de) Kombination von aktiva mit alfuzosin und apomorphin

Legal Events

Date Code Title Description
FF Patent granted
KB Patent renewed